ACTH Stability on Whole Blood

ACTH Clinical Trial

— STABACT  

Official title:

Adrenocorticotropic Hormone Stability on Whole Blood

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04266587
• Other study ID #: 2019/0350/HP
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 2020
• Est. completion date: November 2020

Study information

• Verified date: June 2020
• Source: University Hospital, Rouen
• Contact: Francois FRAISSINET
• Phone: +3323288
• Email: francois.fraissinet[@]chu-rouen.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ACTH is a peptide secreted by pituitary gland and plays an important role in regulating cortisol secretion. ACTH is determined in plasma by immunoassays using specific antibodies. Its determination is difficult because of instability in whole blood. Several factors which influence ACTH stability in blood before analysis have been identified: temperature, hemolysis, time to centrifugation and presence of protease inhibitors. Published results on ACTH whole blood stability seem contradictory.

The objective of this study is to evaluate the effect of aprotinin in 10 healthy volunteers. ACTH measurements will be performed on cobas e602 (Roche Diagnostics, Mannheim, Germany).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: November 2020
• Est. primary completion date: November 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Adult patient aged 18 to 60,

Exclusion Criteria:

• Adult with insufficient venous capital for blood collection

Related Conditions & MeSH terms

• ACTH

Intervention

Biological:
• Blood sampling
blood sampling is done on healthy volunteers

Locations

Country	Name	City	State
France	Rouen University Hospital	Rouen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ACTH concentration in plasma		8 hours